Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Cardiovascular Key Lab of Zhejiang Province, #88 Jiefang Road, Hangzhou, Zhejiang, 310009, China.
Department of Vascular Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, #88 Jiefang Road, Hangzhou, Zhejiang, 310009, China.
Curr Vasc Pharmacol. 2018 Jan 26;16(2):114-124. doi: 10.2174/1570161115666170413145705.
Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
腹主动脉瘤（AAA）是一种进行性的节段性腹主动脉扩张，与高死亡率相关。AAA 的特征是炎症、平滑肌细胞（SMC）耗竭和细胞外基质（ECM）降解。建议进行手术干预和血管内治疗以预防大 AAA 的破裂。不幸的是，目前尚无可靠的药理学药物可用于限制 AAA 的扩张。在过去的几十年中，广泛的研究和正在进行的临床试验旨在确定有效的治疗方法以抑制甚至逆转 AAA 的生长。
在这篇综述中，我们总结了潜在策略的最新进展，特别是大环内酯类、四环素类、他汀类药物、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、皮质类固醇、抗血小板药物和肥大细胞稳定剂。我们还考虑了最近确定的新分子靶点，这些靶点有可能在未来转化为临床实践。
